FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Miravant Medical Technologies Inc. Stock AnalysisComprehensive stock analysis for Miravant Medical Technologies Inc. (MRVT) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMRVT
MRVT
Miravant Medical Technologies Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MRVT
Home🔹Stocks🔹Miravant Medical Technologies Inc.

Miravant Medical Technologies Inc.

MRVT•OTC

Miravant Medical Technologies Inc.

MRVT•OTC
Market cap
$113.57K
Sentiment

Your view on MRVT

Mkt Cap
$113.57K
Sentiment
Your view
MRVT
Miravant Medical Technologies Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MRVT
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Miravant Medical Technologies Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
David E. Mai
Headquarters
336 Bollay Drive, Santa Barbara, CA, US
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
David E. Mai
Headquarters
336 Bollay Drive, Santa Barbara, CA, US
Description

Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors. Miravant Medical Technologies Inc. was formerly known as PDT, Inc. and changed its name to Miravant Medical Technologies Inc. in September 1997. The company was founded in 1989 and is headquartered in Santa Barbara, California.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News